Potentials of ribosomopathy gene as pharmaceutical targets for cancer treatmentOA
Potentials of ribosomopathy gene as pharmaceutical targets for cancer treatment
Ribosomopathies encompass a spectrum of disorders arising from impaired ribosome biogenesis and reduced functionality.Mutation or dysexpression of the genes that disturb any finely regulated steps of ribosome biogenesis can result in different types of ribosomopathies in clinic,collectively known as ribosomopathy genes.Emerging data suggest that ribosomopathy patients exhibit a significantly heightened susceptibility to cancer.Abnormal ribosome biogenesis and dysregulation of some ribo-somopathy genes have also been found to be intimately associated with cancer development.The cor-relation between ribosome biogenesis or ribosomopathy and the development of malignancies has been well established.This work aims to review the recent advances in the research of ribosomopathy genes among human cancers and meanwhile,to excavate the potential role of these genes,which have not or rarely been reported in cancer,in the disease development across cancers.We plan to establish a theoretical framework between the ribosomopathy gene and cancer development,to further facilitate the potential of these genes as diagnostic biomarker as well as pharmaceutical targets for cancer treatment.
Mengxin Wang;Yumei Li;Stephen Vulcano;Changlu Xu;Renjian Xie;Weijie Peng;Jie Wang;Qiaojun Liu;Lee Jia;Zhi Li
Key Laboratory of Biomaterials and Biofabrication in Tissue Engineering of Jiangxi Province,Gannan Medical University,Ganzhou,Jiangxi,341000,China||School of Rehabilitation Medicine,Gannan Medical University,Ganzhou,Jiangxi,341000,ChinaKey Laboratory of Biomaterials and Biofabrication in Tissue Engineering of Jiangxi Province,Gannan Medical University,Ganzhou,Jiangxi,341000,China||School of Basic Medicine,Gannan Medical University,Ganzhou,Jiangxi,341000,ChinaAutoimmunity and Inflammation Program,HSS Research Institute,Hospital for Special Surgery New York,New York,NY,10021,USADivision of Oral and Systemic Health Sciences,School of Dentistry,University of California,Los Angeles,CA,90095,USAKey Laboratory of Biomaterials and Biofabrication in Tissue Engineering of Jiangxi Province,Gannan Medical University,Ganzhou,Jiangxi,341000,China||School of Medical Information Engineering,Gannon Medical University,Ganzhou,Jiangxi,341000,ChinaKey Laboratory of Biomaterials and Biofabrication in Tissue Engineering of Jiangxi Province,Gannan Medical University,Ganzhou,Jiangxi,341000,ChinaInflammation and Immune Mediated Diseases Laboratory of Anhui Province,Anhui Institute of Innovative Drugs,Institute for Liver Diseases of Anhui Medical University,School of Pharmacy,Anhui Medical University,Hefei,230032,ChinaInstitute of Oceanography,Minjiang University,Fuzhou,350108,China
Ribosome biogenesisRibosomopathy geneCancer treatment targetPharmaceutical target
《药物分析学报（英文）》 2024 (003)
308-320 / 13
This research was funded by the National Natural Science Foundation of China(Grant No.:82360542);Jiangxi Provincial Natural Science Foundation,China(Grant Nos.:20224BAB214030 and 20224BAB216072);Doctoral Startup Fund of Gannan Medical University,China(Grant Nos.:QD202136 and QD202132);Science and Technology Planning Projects of Fuzhou,China(Grant No.:2021FZR0101),and the Natural Science Foundation of Fujian Province,China(Grant No.:2022YZ0104).
评论